LENZ as of Oct 31 · 06:53 ET
LENZNasdaqBiological Products, (No Diagnostic Substances)
LENZ Therapeutics, Inc. · Brief
Next report
67 days
Jan 6 · after closeest.Q4 FY26
Expected move
Inputs1 of 7≥ implied
- avg implied
- ±17.1%
- avg realized
- ±11.0%
May 7 '25±17.5%▲+2.09%×0.12
Jul 30 '25±20.3%▼−2.87%×0.14
Q3 FY25±26.3%▼−23.46%×0.89
Jan 7 '26±10.2%▼−6.56%×0.64
Q1 FY26±20.6%▼−17.91%×0.87
May 11 '26±13.5%▼−20.82%×1.55
Q2 FY26±11.3%▼−3.26%×0.29
Oct 28 '26—▲+8.72%—
quarterimplied−30%0+30%realized×
Oct '26—▲+8.72%—
Q2 FY26±11.3%▼−3.26%×0.29
May '26±13.5%▼−20.82%×1.55
Q1 FY26±20.6%▼−17.91%×0.87
Jan '26±10.2%▼−6.56%×0.64
Q3 FY25±26.3%▼−23.46%×0.89
2 older reports
Jul '25±20.3%▼−2.87%×0.14
May '25±17.5%▲+2.09%×0.12
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Jan 6 report · est.—
Linked exposure
LENZ report sessionNo linked exposure.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.